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Summary 
Fetal development is a critical period in the life cycle which
is why the placenta provides a structural and physiological
barrier that protects the fetus from the outer fluctuations
and inner disturbances. A variety of influences from the
environment, however, might induce fetal overexposure to
glucocorticoids that target the fetal hypothalamic-pituitary-
adrenal (HPA) axis and influence the fetal growth trajecto-
ry. Development of the HPA axis starts in the early stages
of pregnancy, but the timing of HPA axis maturation and
the glucocorticoid receptor (GR) expression in relation to
birth is highly species-specific. The functional state of the
fetal HPA axis plays a key role in the maturation of many
organs necessary for intrauterine development and exis-
tence after birth. A functional HPA axis in near-term fetus-
es provides an adequate response to stress and also affects
the timing of parturition. Due to their potent effect on the
maturation of fetal tissues, synthetic glucocorticoids are
used in human pregnancy at risk of preterm delivery.
Dexamethasone and betamethasone, as the ones most
commonly used, cross the placental enzymatic barrier
(11b-hydroxysteroid dehydrogenase type 2 – 11b-HSD2)
and have 25-fold higher affinity to the GR than endoge-
nous glucocorticoids, stimulating many aspects of fetal
maturation. Despite the numerous positive effects, expo-
sure to synthetic glucocorticoids during fetal development
may result in intrauterine growth retardation and fetal pro-
gramming of the HPA axis function which is associated with
cardiovascular, metabolic and psychiatric disorders mani-
fested later in life. Long-term consequences indicate the
need for the implementation of new studies that will pro-
Kratak sadr`aj
Fetalni razvoj predstavlja kriti~an period tokom `ivotnog
ci klusa, zbog ~ega placenta obezbe|uje strukturnu i fizio-
lo{ku barijeru koja {titi fetus od spolja{njih kolebanja i
unutra{njih poreme}aja. Brojni uticaji iz okru`enja mogu
dovesti do izlaganja fetusa povi{enoj koncentraciji gluko -
kor tikoida koji deluju na fetalnu hipotalamo-hipofizno-
adrenalnu (HPA) oso vinu i uti~u na rast. Razvoj HPA oso-
vine po~inje veoma rano tokom gestacije, ali vreme njenog
sazrevanja i ekspresije glukokortikoidnog receptora (GR) u
odnosu na ro|enje je specifi~no za svaku vrstu. Fetalna
HPA osovina ima klju~nu ulogu u sazrevanju brojnih orga -
na tokom intrauterinog raz voja neophodnih za pre`ivljava -
nje nakon ro|enja, obezbe |uje adekvatan odgovor fetusa
na stres, a uti~e i na vreme poro|aja. Usled sna`nog utica-
ja na sazrevanje fetalnih tkiva, sintetski glukokortikoidi se
upotrebljavaju tokom rizi~nih trudno}a kod kojih postoji
opasnost od prevremenog poro|aja. Deksametazon i beta -
metazon, kao naj~e{}e kori{}eni lekovi u antenatalnoj te -
rapiji, prolaze enzimsku placentalnu barijeru (11b-hidro -
ksisteroid dehidrogenaza tip 2 – 11b-HSD2) i imaju 25
puta ve}i afinitet vezivanja za GR u odnosu na endogene
gluko kortikoide, stimuli{u}i mnoge procese sazrevanja fe -
tusa. Uprkos brojnim pozitivnim efektima, izlaganje sintet-
skim glukokortikoidima tokom fetalnog razvoja mo`e rezul-
tirati retardacijom rasta fetusa i programiranjem fetalne
HPA funkcije. Nastale promene su povezane sa kardio -
vaskular nim, metaboli~kim i psihijatrijskim poreme}ajima,
koji se mogu manifestovati tokom `ivotnog ciklusa. Dugo -
trajne posledice antenatalnog tretmana ukazuju na potrebu
za novim studijama, koje bi obezbedile bolje razumevanje
veze izme|u izlo`enosti povi{enim koncentracijama gluko -
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Pregnancy and the HPA axis
In adults, psychological or physical stress acti-
vates the hypothalamic-pituitary-adrenal (HPA) axis.
Hypothalamic corticotrophin-releasing hormone
(CRH) stimulates adrenocorticotropic hormone
(ACTH) release from the anterior pituitary, which, in
turn, causes the release of adrenal glucocorticoids.
Adrenal glucocorticoids are dominantly involved in
protein, carbohydrate and lipid metabolism, and
strongly affect immune response with the primary goal
of achieving homeostasis. An elevated glucocorticoid
level provoked by chronic stress exposure exerts long-
term changes in negative feedback control at the
hypothalamic and pituitary level, while rapid glucocor-
ticoid feedback suppression of basal and stress-
induced HPA axis activity is controlled through a cen-
tral site of action and involves activation of the
glucocorticoid receptor (GR) (1). 
During pregnancy, numerous adaptations of
maternal anatomy and physiology provide optimal
conditions and maximal security for the developing
fetus, from the environmental fluctuations and inner
disturbances (2). The placenta represents a feto-
maternal exchange barrier to many of the maternal
factors, although sufficient amounts of nutrients and
oxygen are delivered to the developing fetus, where-
as fetal metabolic excretion products are removed,
enabling optimal fetal growth (3). Although the pla-
centa shows broad species-specific differences, the
common histological structure includes the maternal
blood vessels endothelium (endometrium) and the
fetal blood vessels endothelium (chorion). At the ear-
liest stage of development, the principal precursor of
the fetal part of the placenta is the trophoblast, evi-
dent as a thin cellular layer surrounding the blasto-
cyst. During implantation, the trophoblast becomes
the chorion, which is in direct contact with uterine
endometrial connective tissue and differentiates into
syncytiotrophoblast, a multinucleated cytoplasmic
mass or syncytium that arises from the fusion of sep-
arate cells of the underlying cytotrophoblast. The
functional part of maternal placenta evolves from the
uterine epithelium. The placental exchange area is
villous in primates and sheep, and has the form of a
labyrinth in mice, rats and guinea pigs (4). 
Placental endocrine function creates a unique
endocrine milieu providing the production of hypo-
thalamic and pituitary hormones, as well as growth
factors. The quantity of synthesized adrenal and
gonadal hormones, using substrates of maternal and
fetal origin, indicates intensive steroidogenic activity
in the placenta. Placental CRH is secreted in large
amounts into the maternal and fetal circulation influ-
encing the maternal and fetal HPA axis function. In
human CRH immunoreactivity was present in hypo-
thalamic paraventricular nuclei (PVN) as early as at
12 weeks of gestation, but intensive hypothalamic
stimulation of pituitary corticotropes started from
week 16–30 of gestation (4, 5). Further trophic sup-
port of the adrenal gland growth and differentiation
by the released ACTH becomes evident from around
mid gestation towards the term, but there is no clear
correlation between the level of plasma ACTH and
glucocorticoid concentrations, suggesting immaturity
of the negative feedback regulation during fetal
development. In rats, significant hypothalamic sup-
port of ACTH synthesis and release and promotion of
adrenal gland growth and functional differentiation
started later, during the last third of gestation. The
functioning of negative feedback control was verified
by the decreased CRH expression before birth (4, 6). 
Contrary to the hypothalamic CRH, placental
CRH is positively stimulated by the increasing cortisol
level that additionally up-regulates CRH gene expres-
sion establishing a feed forward loop (4). Circulating
CRH influences fetal pituitary ACTH production and
directly stimulates dehydroepiandrosterone (DHEA),
dehydroepiandrosteronesulphate (DHEAS) and corti-
sol output from the fetal adrenals. The secreted
DHEAS serves as a substrate for placental estrogen
production due to aromatase activity. The created
estrogen/progesterone ratio forces interconversion of
the biologically active cortisol to inactive cortisone,
thereby decreasing negative feedback drive of the
higher control centers, and consequently hypothala-
mic CRH and pituitary ACTH output are enhanced
and further stimulate the growth of fetal adrenal
glands (7). In humans and primates, this mechanism
has enabled the size of near-term adrenal glands to
surpass several times the relative size of adult ones,
primarily due to the enormously developed fetal zone,
while the quantity of synthesized steroids 5 times sur-
passes the stimulated steroid production in adults. On
the other hand, a centrally positioned fetal zone,
responsible for androgen production during pregnan-
cy, disappears during the postnatal period. In new-
borns, dramatic shrinkage of adrenal glands takes
place due to involution of the fetal zone caused by
apoptotic cell death (4, 8). In rodents, as short gesta-
tional period species, adrenal glands synthesize glu-
cocorticoids and aldosterone, but they are unable to
produce androgens (9). Instead, androgens are pro-
duced during gestation in the placenta, maternal cor-
vide a better understanding of the link between glucocorti-
coid overexposure during fetal development and adverse
outcomes in adulthood.
Keywords: programming, fetal development, HPA axis,
dexamethasone, betamethasone, antenatal therapy
kortikoida tokom fetalnog perioda i {tetnih posledica u
odraslom dobu.  
Klju~ne re~i: programiranje, fetalni razvoj, HPA osovina,
deksametazon, betametazon, antenatalna terapija
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pus luteum and in the fetal gonads (10). Thus, the
placenta and the fetal adrenals make a unique feto-
placental functional unit that controls and adjusts
HPA axis functioning during in utero development. 
HPA axis function during development
Prenatal presence of the GR has been demon-
strated in the tissue derivatives of all three germ lay-
ers using in situ hybridization and immunocytochemi-
cal techniques. Strictly defined temporal and spatial
expression of the GR, in fact, defines the target tis-
sues and periods of glucocorticoid sensitivity during
development. The established increase in GR mRNA
amount just before the final differentiation step for
each glucocorticoid target tissue, and the following
decrease in GR mRNA amount upon differentiation,
suggest that maturational events are controlled by
glucocorticoids (11). 
Activity of the fetal HPA axis and the released
glucocorticoids direct the fetal growth trajectory to a
considerable extent, according to the maternal ener-
gy resources. Glucocorticoids promote fetal matura-
tion, as they affect the developmental and matura-
tional processes of a variety of tissues and organs, in
order to enable functional adaptations requested for
extrauterine survival. Under constantly changing envi-
ronmental conditions, the survival of newborns
depends on the maintenance of homeostasis, ther-
mogenesis and a stable energy supply, in view of the
transition from placental to enteral nutrition (12). To
achieve this, glucocorticoids influence the timely dif-
ferentiation of vital organ systems, including the cen-
tral nervous system, gastrointestinal system, as well as
other endocrine axes and tissue hormones sensitivity.
Fetal lung maturation and surfactant production,
enhancement of gluconeogenic enzyme activities in
the liver and glycogen deposition, as well as adaptive
thermogenesis in brown adipose tissue are also con-
trolled by glucocorticoid action (12–14). 
Like in adults, where stress implicates an HPA
axis response, adverse intrauterine conditions in fetus-
es also provoke fetal HPA axis activation (15). For
example, fetal hypoxemia leads to an increase in the
fetal ACTH concentration with up-regulation of
mRNAs of the ACTH receptor and steroid-synthesiz-
ing enzymes in the adrenals that result in selective
increase of cortisol synthesis in fetal sheep (16).
Negative feedback control of the HPA axis by gluco-
corticoids begins to operate near the term, suggesting
that active control of the glucocorticoid level is indis-
pensable even during fetal development (17). 
Coordinative activity of the HPA axis and the pla-
centa in fetuses plays an important role in determin-
ing gestation length, which is certainly closely related
to the maturation level of numerous organ systems.
Although the exact mechanism remains unclear, an
increase in fetal HPA activity has been established in
humans and primates during late gestation. An
increased cortisol concentration, that is generated
locally in the placenta or derived systemically, stimu-
lates prostaglandin synthesis, decreasing its metabo-
lism, which results in an enhanced prostaglandin out-
put. Huge amounts of DHEAS, produced by the fetal
adrenals, undergo aromatization in the placenta and
subsequently lead to elevated circulating estrogen
levels (18). The created hormonal milieu and
enhanced output of prostaglandins induce the
expression of oxytocin receptors indispensable for
uterine contractility. Late in gestation, an increase in
unbound CRH fraction intensifies circulation in the
feto-placental unit, potentiating the effects of local
mediators and hormones that further up-regulate
myometrial contractility and represent an important
step in the initiation of birth (4, 19). 
Antenatal treatment
Fetal growth and the development of fetal tis-
sues and organs are dependent on many factors,
including the hormonal environment. As mentioned,
endogenous glucocorticoids produced by the fetal
adrenal glands have a crucial role in these processes
and exert beneficial effects on the maturation of fetal
tissues where GR have been located. The timing of
HPA axis maturation and expression of the genes
encoding GR in relation to birth is highly species-spe-
cific. In species with a long gestational period (sheep,
guinea pigs, primates and humans) that give birth to
mature young, maximal brain growth and many
aspects of neuroendocrine maturation take place in
utero. But in species with short gestational periods
(rats, rabbits and mice) that give birth to immature
offspring, much of the neuroendocrine development,
GR genes expression as well as the final maturation of
endocrine axes occur in the postnatal period (20).
Under normal circumstances, glucocorticoid levels
are significantly lower in the fetus than in the mother
and transplacental glucocorticoid diffusion is normal-
ly limited by the actions of the placental barrier
enzyme, 11b-hydroxysteroid dehydrogenase type 2
(11b-HSD2) (21). This enzyme plays a key role in
regulating glucocorticoid concentrations in the fetal
circulation by inactivating maternal glucocorticoids at
the level of the placenta, and protects fetuses from
glucocorticoid overexposure. In a rat and human
study, it has been demonstrated that attenuated activ-
ity of 11b-HSD2 due to carbenoxolone application,
maternal exposure to stress or antenatal treatment
with synthetic glucocorticoids may expose the fetus to
inappropriately high levels of glucocorticoids, which
leads to reduced fetal growth followed by long-lasting
consequences (12). 
Due to their potency in maturating tissues and
organs, synthetic glucocorticoids have been used for
more than 40 years in human pregnancies at risk of
preterm delivery. Antenatal glucocorticoid administra-
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tion is perhaps one of the most effective prenatal
interventions for the prevention of complications
related to preterm birth, which include respiratory dis-
tress syndrome (RSD), intraventricular hemorrhage
and, most importantly, neonatal mortality. The origin
of this practice comes from Liggins and Howie (22),
whose preliminary results indicated a reduction in the
incidence of RSD and mortality in humans after
maternal betamethasone treatment. Subsequent
trials have confirmed the efficacy of this treatment in
the reduction of complications associated with
preterm delivery (23). According to the National
Institutes of Health (NIH), all the fetuses between 24
and 34 weeks of gestation at risk of preterm delivery
are potential candidates for antenatal glucocorticoid
treatment. The recommended treatment consists of
two doses of 12 mg betamethasone administered
intramuscularly 24 h apart, or four doses of 6 mg dex-
amethasone every 12 h. They cross the placental bar-
rier, have 25-fold higher affinity to the GR than
endogenous glucocorticoids, and act in accordance
with its nuclear transcription factor function (24). The
question of the relative risk and benefit of repetitive
courses of prenatal glucocorticoid administration is
still open. 
Antenatal glucocorticoid therapy is indicated in
women with premature rupture of membranes and
women with progestational or gestational diabetes at
risk of preterm delivery, but contraindicated in cases
of maternal systemic infections including tuberculosis
(24). 
During gestation, synthetic glucocorticoids are
also used to treat several other clinical conditions of
the mother, such as autoimmune diseases, allergies
and asthma. The incidence of congenital adrenal
hyperplasia (CAH) in fetuses is rare, but treatment
with glucocorticoids is necessary to improve later out-
come. In contrast to antenatal therapy applied in
preparation for preterm birth, treatment under these
clinical conditions often begins early in the pregnan-
cy and lasts throughout gestation (25). 
Figure 1 Synthetic glucocorticoids, such as dexamethasone and betamethasone, are used in antenatal therapy, cross the
enzymatic placental barrier (11ß-hydroxysteroid dehydrogenase type 2 – 11ß-HSD2) and lead to fetal glucocorticoid over -
exposure. They affect GR/MR expression in the hippocampus and cause inhibition of the HPA axis function during fetal devel -
opment. Molecular and cellular changes established during fetal development reflect on postnatal functioning of the HPA axis.
The altered set point of HPA axis feedback regulation from the hippocampus leads to HPA axis deregulation under basal and
stress conditions in offspring. Alterations of HPA axis functioning in adults, due to fetal glucocorticoid overexposure, are asso-
ciated with an increased risk of cardiovascular, metabolic and psychiatric disorders.
Despite the mentioned positive effects, repeated
doses of antenatal glucocorticoids have potentially
negative effects on fetal growth and adverse effects
on brain growth and development in animals and
humans. Impaired intrauterine growth and low birth
weight, as markers of an adverse in utero environ-
ment, are associated with hypertension, glucose intol-
erance, insulin resistance, type 2 diabetes, dyslipid -
aemia, obesity, reproductive and brain disorders in
adulthood (20, 26). The phenomenon is known as
programming. The concept of early life programming
explains the link between prenatal environmental
events, altered fetal growth and development, and
later pathophysiology (27). Maternal undernutrition,
placental insufficiency and exposure to glucocorti-
coids that includes maternal stress or antenatal gluco-
corticoid therapy are the most common conditions
that lead to intrauterine growth retardation (IUGR)
associated with programmed outcomes in adulthood.
Such conditions ultimately result in fetal glucocorti-
coid overexposure, since they mediate the program-
ming effects of nutritional and other environmental
challenges during pregnancy (28). The nature of the
modifications that occur as a consequence of gluco-
corticoid overexposure is dependent on the dose and
timing of the exposure (Figure 1).
Antenatal glucocorticoid therapy reduces mor-
tality and morbidity in preterm babies and at the same
time increases the risks of dysregulation of the meta-
bolic function and endocrine axes, including stress
response, growth and reproduction (12). More ran-
domized human follow-up studies are needed to bet-
ter understand the short-term benefits and long-term
consequences of antenatal exposure to synthetic glu-
cocorticoids on development and health.
Antenatal treatment and fetal HPA axis
function 
Results from animal and human studies demon-
strate that fetal glucocorticoid overexposure results in
fetal growth retardation that persists for a prolonged
period after birth. The developing HPA axis is espe-
cially sensitive to glucocorticoid overexposure, as they
strongly affect the establishment of HPA axis structure
and function (29). Glucocorticoids control the prolif-
erative activity of cells at all the HPA axis levels, and
influence the gene expression of receptors, enzymes,
ion channels, as well as cytoarchitectural proteins. All
these changes at the cellular and molecular level
result in altered set points of the delicate hormonal
feedback mechanisms that become evident during
the life cycle, under basal or stress circumstances (12,
29, 30).
The hippocampus has a central role in the neg-
ative-feedback regulation of HPA axis by glucocorti-
coids which interact with the abundantly expressed
GR and mineralocorticoid receptors (MR). Appli -
cation of synthetic glucocorticoids during pregnancy
provokes a sex-specific influence according to hip-
pocampal mRNA GR and MR levels in fetuses. Single
maternal Dx exposure results in significant increases
in MR and GR mRNA in the CA1–2 region of the hip-
pocampus, and MR mRNA in the dentate gyrus in
female fetuses, while changes are absent in male
guinea pig fetuses (31). After multiple maternal treat-
ment with Dx, marked increases in MR mRNA level in
the hippocampus of female fetuses were recorded,
while in males enhancement of GR mRNA was shown
in limbic structures indicating changed hippocampal
feedback sensitivity to glucocorticoids, natural or syn-
thetic (32). Quantitative in situ hybridization demon-
strated that the MR mRNA level is transiently
decreased after a single Dx injection in the mouse
fetus (33). Synthetic glucocorticoids applied during
pregnancy lead to reduction in brain weight in fetus-
es. Literature data show similar effects of fetal gluco-
corticoid overexposure in different species, including
mice, rhesus macaques and humans, such as
reduced hippocampal volume with a reduced number
of pyramidal neurons and pronounced degeneration
of neuronal perikarya and dendrites, resulting in a
decreased number of synaptic contacts (34, 35).
Epigenetic changes caused by antenatal treatment
with synthetic glucocorticoids that alter genome-wide
transcription and modify GR DNA binding in the fetal
hippocampus during late gestation have been recent-
ly shown in guinea pigs (36).
The hypothalamus, as the main site for gluco-
corticoid negative feedback, represents a regulatory
place where the stress response starts and terminates.
Neurons in the parvocellular division of the hypothal-
amic paraventricular nuclei (PVN) synthesize both
CRH and AVP, or only CRH, and their axons project to
the median eminence where the produced neuropep-
tides are released. Repeated fetal glucocorticoid
exposure to synthetic glucocorticoids, dexametha-
sone or betamethasone, inhibits fetal HPA function,
as significantly decreased levels of CRH mRNA in the
hypothalamic PVN in both male and female fetuses
were established (32). Delay of CRH release in the
external zone of the median eminence, shown by
immunocytochemistry, might further confirm the
decreased synthetic activity of CRH neurons in the
fetus and neonatal offspring after fetal Dx exposure
(37). Delicate cellular and molecular changes caused
by the changed glucocorticoid milieu during develop-
ment become evident at the level of hypothalamic
neurosecretory cells morphometric parameters in
fetuses and during the neonatal period (38). Analysis
of neurosecretory parvocellular and magnocellular
PVN neurons suggested that the area and diameter
of neurosecretory cells nuclei at the levels were CRH
neurons are dominantly positioned are significantly
changed under the influence of dexamethasone, but
the range of changes depends on the timetable and
dosage of dexamethasone applied (39). 
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As a consequence of the antenatal treatment,
the quantity and time profile of hypothalamic CRH
released into the hypophyseal portal blood along with
other ACTH secretagogues such as AVP change, and
this reflects on the differentiation and activity of ante-
rior pituitary corticotropes and the secreted ACTH.
Prenatal glucocorticoid exposure also directly influ-
ences the fetal pituitary, as GR are present in pituitary
primordial cells. Again, the timing and regime of fetal
glucocorticoid exposure in utero will determine the
outcome, as regards the establishment of hormone-
producing cell populations in the anterior pituitary.
Glucocorticoid impact on the proliferative activity of
immature and differentiated ACTH cells results in a
decrease of their number in near-term rat fetuses (40,
41). Multiple Dx administration during the last third of
rat gestation also provokes marked inhibitory ultra-
structural changes, most prominent at the level of
synthetic organelles such as the endoplasmic reticu-
lum and Golgi complex, accompanied by reduced
ACTH levels during the fetal and neonatal period
(39). On the contrary, in sheep fetuses, Dx exposure
in early pregnancy did not reduce the POMC mRNA
pituitary level and circulating ACTH concentration
(42).
Maternal glucocorticoid administration influ-
ences numerous processes during the establishment
of fetal adrenal gland structure and function, includ-
ing adrenal gland growth, formation of a centrally
positioned medulla, expression pattern of the key
steroidogenic enzymes, level of ACTH receptor
expression, and consequently glucocorticoid output
(43, 44). In rat fetuses, a marked decrease of the
fetal adrenal gland volume as a consequence of the
decreased proliferative activity in the adrenal gland
periphery, which is the region of the adrenal cortex
where most proliferating cells were found, has been
established after intrauterine exposure to glucocorti-
coids (Figure 2). Even the mitotic activity of sympa-
thoadrenal precursor cells – chromoblast that simulta-
neously migrate into the adrenal anlage and
proliferate was inhibited under glucocorticoid influ-
ence (45, 46). Decreased expression of steroidogenic
enzyme CYP17 after antenatal exposure to synthetic
glucocorticoids has been reported, reflecting the per-
sistence of the adrenal gland functional changes in
guinea pigs (47). In fetal sheep, an acute effect of Dx
exposure early in pregnancy resulted in a transient but
significant decrease in plasma cortisol levels, followed
by significant elevation in both female and male near-
term fetuses. This may be attributed to an increased
expression of the key steroidogenic enzymes in the
adrenals, such as P450C 17 and 3-HSD mRNA in
female fetuses. In the adrenal glands of male fetuses
other types of changes have been reported including
a reduced expression of ACTH receptor mRNA level
(42).
Antenatal treatment, HPA axis function
and long-term consequences 
As presented, excessive glucocorticoid exposure
during intrauterine development shapes the develop-
mental profile at all the HPA levels, altering the set
points of the offspring HPA axis feedback regulation.
A decreased expression level of the GR and MR in
limbic structures has been associated with reduced
negative-feedback drive and increased HPA axis activ-
Figure 2 Central section of the adrenal gland of 21-day-old fetuses of control (C) and Dx treated (Dx) mothers during preg-
nancy. In control fetuses the main part of the adrenal gland is occupied by steroidogenic tissue composed of the zona glomeru-
losa (ZG) positioned at the periphery and inner zone (IZ), while in the central part formation of the adrenal medulla i.e. cen-
tripetal migration of chromoblast takes place. In the fetuses from Dx treated mothers the volumes of the adrenal gland and all
its parts were significantly reduced.
ity in offspring. Elevated basal corticosterone levels or
a greater corticosterone response to stressful stimuli
have been recorded, depending of the timing and
dosage of fetal glucocorticoid exposure during preg-
nancy, in adult rats and sheep (48, 49). Sex-specific
alterations in the HPA axis function and glucocorti-
coid output under basal or stress conditions during
adulthood have been shown in guinea pigs as conse-
quences of antenatal glucocorticoid exposure (50). In
humans with low birth weight, increased cortisol
response to stressful stimuli and ACTH hormone
application as well as high fasting plasma cortisol lev-
els were shown (51). 
Growth retardation and the presented long-term
deregulation of HPA axis function under glucocorti-
coid influence are the underlying mechanisms linking
fetal development with postnatal health, including
higher susceptibility to cardiovascular and metabolic
diseases, as well as reproductive disorders (2, 52).
Excessive glucocorticoid exposure causes major struc-
tural and metabolic alterations in numerous tissues
during the period of tissue plasticity that actually rep-
resent an adaptive fetal response with permanent
consequences (53). For example, glucocorticoids
affect the development of the kidney by reducing the
number of nephrons, influence the activity of the ren-
nin–angiotensin system and vascular responsiveness
to angiotensin II, increasing the risk of cardiovascular
diseases or hypertension in offspring subject to exces-
sive glucocorticoid exposure during in utero develop-
ment (54). Exposure to high glucocorticoid levels
leads to a reduction of the insulin producing cells
mass and their functional capacity during the fetal
period. In addition, changed profiles of glucose toler-
ance and insulin sensitivity with enhanced glucose
production and reduced glucose utilization in the
major metabolic tissues, such as the liver, skeletal
muscle and adipose tissue, become evident during
the life cycle. Thus, the prenatal glucocorticoid envi-
ronment might increase susceptibility to metabolic
syndrome and metabolic diseases such as type 2 dia-
betes in adult offspring (55, 56).
Glucocorticoid exposure during early life creates
an environment that the fetus recognizes as hostile
conditions and this is followed by permanent changes
in the HPA axis functioning. As a consequence, long-
term neurodevelopmental changes might be pro-
voked with adverse effects on neuromotor and cogni-
tive functions, causing behavioral problems, even
attention deficit hyperactivity disorders during adoles-
cence (53–57). Even schizophrenia, anxiety or autis-
tic disorders may be explained by the developmental
origin of the disease hypothesis concept (58).
Emerging evidence from animal studies and several
human studies suggests that prenatal epigenetic
changes are, at least in part, linked to an increased
risk for the development of mental diseases during
the life cycle (59).
Concluding remarks
The HPA axis begins functioning during fetal
development and controls several of its important
aspects, including fetal tissue maturation due to
enable adaptations requested for extrauterine sur-
vival, fetal stress response and the initiation of birth.
Antenatal glucocorticoid administration is often
used in clinical practice when the risk of preterm
delivery persists. Short-term beneficial effects of pre-
natal glucocorticoids in fetal tissue maturation are, at
the same time, the ones that increase the long-term
risks of different types of dysregulation manifested in
adulthood.
Exposure to synthetic glucocorticoids during
pregnancy provokes a sex-specific influence accord-
ing to hippocampal mRNA GR and MR levels in fetus-
es that reflects on HPA axis function during in utero
development. 
Molecular and cellular changes established dur-
ing fetal development reflect on postnatal functioning
of the HPA axis. Sex-specific alterations in HPA axis
functioning with reduced negative feedback drive
from the hippocampus lead to increased HPA axis
activity in offspring, under basal or stress conditions,
depending on the timing and dosage of glucocorti-
coids applied.
A growing amount of information obtained from
animal and human studies has offered evidence that
link alterations of the HPA axis functioning due to
fetal glucocorticoid exposure with an increased risk of
cardiovascular, metabolic and psychiatric disorders.
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